Wolf-Hagen Schunck

Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.

John R. Falck

John R. Falck is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids.

Dominik Müller

Dominik N. Mueller is pharmacist and group leader at the Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 25 years of research experience in the field. His current work is focused on the crosstalk between immune cells, vasculature and target organs of hypertension. His research group’s major research interests are beside the understanding of pathomechanisms leading to cardiovascular disease, the identification of cardiovascular risk factors and new target for treatment.

Robert Fischer

Robert Fischer is a board-certified medical doctor in internal medicine and worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin. He has long-term professional experience as principle investigator and sub-investigator in several cardiovascular clinical trials. At Max-Delbrueck-Center for Molecular Medicine, Dr. Fischer led a research group and established methods to analyze arrhythmia mechanisms in animal models.

Karen Uhlmann

Karen Uhlmann has more than 20 years experience in IP Asset Management, being instrumental in partnering a multitude of innovative technologies from academia to biotech and pharma companies, closing option and license agreements, raising funds, drafting and executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin.